Envista (NYSE:NVST) Given Hold Rating at Needham & Company LLC

Envista (NYSE:NVST)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other research firms have also recently commented on NVST. Wells Fargo & Company increased their price target on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Morgan Stanley increased their price objective on shares of Envista from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 6th. Jefferies Financial Group boosted their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Piper Sandler upped their price target on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Finally, Mizuho started coverage on shares of Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Envista currently has an average rating of “Hold” and an average target price of $20.21.

Envista Stock Down 1.9 %

NYSE:NVST opened at $18.28 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The stock has a market capitalization of $3.15 billion, a P/E ratio of -2.82, a P/E/G ratio of 1.27 and a beta of 1.33. The company’s 50-day simple moving average is $20.27 and its 200-day simple moving average is $19.69. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $23.00.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, equities analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Trading of Envista

Several institutional investors have recently bought and sold shares of the business. Ariel Investments LLC lifted its position in shares of Envista by 6.2% during the 4th quarter. Ariel Investments LLC now owns 12,059,624 shares of the company’s stock valued at $232,630,000 after buying an additional 699,625 shares in the last quarter. Nuance Investments LLC lifted its holdings in Envista by 4.4% during the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after purchasing an additional 308,221 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Envista by 72.6% in the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after purchasing an additional 2,882,844 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Envista by 19.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after purchasing an additional 1,089,923 shares in the last quarter. Finally, Gates Capital Management Inc. increased its stake in shares of Envista by 15.1% during the fourth quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company’s stock worth $90,550,000 after purchasing an additional 615,577 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.